[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335596-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335596-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","early-administration-of-anamorelin-improves-cancer-cachexia-in-gastrointestinal-cancer-patients-an-observational-study","Early administration of anamorelin improves cancer cachexia in gastrointestinal cancer patients: an observational study","","Early administration of anamorelin is evaluated for its ability to improve cancer cachexia in patients with colorectal and gastric cancer undergoing systemic chemotherapy. Real-world retrospective data were collected from 43 cachexia patients treated with anamorelin between June 2021 and October 2022. Efficacy was assessed by changes in appetite and body weight gain at 3 and 12 weeks. Multivariate results link earlier treatment before second-line chemotherapy and colorectal cancer with appetite and weight gains.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/early-administration-of-anamorelin-improves-cancer-cachexia-in-gastrointestinal-cancer-patients-an-observational-study/335596/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/early-administration-of-anamorelin-improves-cancer-cachexia-in-gastrointestinal-cancer-patients-an-observational-study/335596.png","ImageObject",300,407,{"name":42,"@type":43},"Evangeline","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of the observational study on anamorelin?","Question",{"text":63,"@type":64},"To assess the efficacy of anamorelin in colorectal and gastric cancer patients with cancer cachexia and to identify factors associated with its effectiveness in real-world care.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was cachexia defined in the study?",{"text":68,"@type":64},"Cachexia was defined as weight loss exceeding 5% within six months plus at least two symptoms such as fatigue or muscle weakness, and at least one lab or clinical condition including elevated CRP, low hemoglobin, or low albumin.",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes were used to evaluate anamorelin efficacy?",{"text":72,"@type":64},"Appetite improvement and body weight (BW) gain were measured after 3 and 12 weeks.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335596,1790148807,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nEarly administration of anamorelin improves cancer cachexia in gastrointestinal cancer patients: an observational study  \nToshihiko Matsumoto1,2􀀍, Sien Cho2, Akio Nakasya2, Hiroki Nagai2, Hironaga Satake2,3 & Hisateru Yasui2  \nTo report the efficacy of anamorelin in patients with colorectal and gastric cancer with cachexia and in those receiving systemic chemotherapy. We retrospectively collected real-world data from patients diagnosed with colorectal and gastric cancers experiencing cachexia who were treated with anamorelin. We evaluated the efficacy of treatment by measuring the improvements in appetite and body weight (BW) gain. Between June 2021 and October 2022, 43 cancer patients with cachexia—23 with gastric cancer and 20 with colorectal cancer—were treated with anamorelin. Median observation period was 7.3 months. The participants were 25 males with median age of 71 years and median BMI of 19.7. The ECOG PS distribution was 4, 33, 6 for grades 0, 1, and 2, respectively. Seven patients received supportive care only, while 36 received anamorelin with chemotherapy. Thirty-four had received chemotherapy previously (≤ 2 regimens) and nine had received ≥ 3 regimens. Median anamorelin treatment duration was 2.8 months; overall survival was 7.3 months. After 3 weeks, 24 experienced appetite improvement and 21 gained weight; after 12 weeks, 20 experienced appetite improvement and 15 gained weight. Multivariate analysis showed that anamorelin treatment before second-line chemotherapy and colorectal cancer correlated with appetite improvement and weight gain at  \n3 weeks. In the univariate analysis, anamorelin treatment before second-line chemotherapy correlated with weight gain at 12 weeks and with improved overall survival in patients with weight gain at  \n12 weeks. Early anamorelin treatment contributes to appetite improvement and BW gain in colorectal and gastric cancers with cachexia.  \nKeywords Anamorelin, Retrospective study, Cachexia, Cancer  \nPatients with advanced cancer may experience a systemic condition known as cancer cachexia, which is characterized by weight loss caused by changes in fat and skeletal muscle tissue mass that can weaken the ability of the patient to withstand anticancer treatment, diminish the quality of life, and worsen the prognosis 1,2. Cachexia affects approximately 80% of patients with advanced cancer 3,4 and accounts for approximately 30% of cancer-related deaths 5–9. Furthermore, up to 80% of patients with advanced gastric cancer (GC) develop cachexia 10, as do 37–50 .4% of patients with unresectable colorectal cancer (CRC) 11, 12.  \nCancer cachexia causes metabolic changes that negatively affect the quality of life of patients and reduce their tolerance to chemotherapy 13, 14. Furthermore, cancer cachexia is a poor prognostic factor in patients with cancer, including those with GC and CRC 4, 15, 16. The prevention and treatment of cachexia in patients with advanced cancer have become an important issue.  \nAnamorelin is an oral ghrelin mimetic and selective agonist that exerts its action at the ghrelin receptor, improves appetite, and affects metabolism. Clinical trials in Japan have shown that anamorelin effectively manages cancer cachexia by increasing lean body mass, body weight (BW), and alleviating anorexia-related symptoms 17–19. Following these trials, anamorelin was approved in Japan in January 2021 for the management of cachexia in patients with non-small cell lung cancer (NSCLC), GC, CRC, and pancreatic cancer. However, the number of patients enrolled in clinical trials for gastrointestinal cancer was small, with only 45 cases of GC and  \n1Department of Medical Oncology, Ichinoimiya Nishi Hospital, 1, Kaimei Aza Hira, Ichinomiya City, Aichi 4940001, Japan. 2Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe City, Hyogo, Japan.  \n3Department of Medical Oncology, Kochi Medical ","cbCaiaypX3OFMv4Z","https://ap.wps.com/l/cbCaiaypX3OFMv4Z","pdf",1581639,"English","# Materials and methods\n## Patients\n## Treatment\n## Evaluation and statistical analysis","[{\"question\":\"What was the purpose of the observational study on anamorelin?\",\"answer\":\"To assess the efficacy of anamorelin in colorectal and gastric cancer patients with cancer cachexia and to identify factors associated with its effectiveness in real-world care.\"},{\"question\":\"How was cachexia defined in the study?\",\"answer\":\"Cachexia was defined as weight loss exceeding 5% within six months plus at least two symptoms such as fatigue or muscle weakness, and at least one lab or clinical condition including elevated CRP, low hemoglobin, or low albumin.\"},{\"question\":\"What outcomes were used to evaluate anamorelin efficacy?\",\"answer\":\"Appetite improvement and body weight (BW) gain were measured after 3 and 12 weeks.\"}]","Early administration of anamorelin improves cancer cachexia in gastrointestinal cancer patients: an observational study | PDF",1790011559,23]